Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

[Validation and comparison of pharmacogenetics-based warfarin dosing algorithms in Han Chinese patients].

Yu LP, Song HT, Zeng ZY, Wang QM, Qiu HF.

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Jul;40(7):614-9. Chinese.

PMID:
22943693
2.

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O.

Int J Clin Pharm. 2012 Dec;34(6):837-44. doi: 10.1007/s11096-012-9678-3. Epub 2012 Jul 27.

PMID:
22851439
3.

Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement.

Tan SL, Li Z, Song GB, Liu LM, Zhang W, Peng J, Zhang T, Jia FF, Zhou G, Zhou HH, Zhou XM.

Pharmazie. 2012 Nov;67(11):930-7.

PMID:
23210243
4.

Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial.

Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q.

Int J Med Sci. 2012;9(6):472-9. doi: 10.7150/ijms.4637. Epub 2012 Aug 10.

5.

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.

Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM.

Pharmacogenet Genomics. 2009 Mar;19(3):226-34. doi: 10.1097/FPC.0b013e328326e0c7.

PMID:
19177029
6.

Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement.

Zhao L, Chen C, Li B, Dong L, Guo Y, Xiao X, Zhang E, Qin L.

PLoS One. 2014 Apr 11;9(4):e94573. doi: 10.1371/journal.pone.0094573. eCollection 2014.

7.

Verification of five pharmacogenomics-based warfarin administration models.

Lin M, Yu L, Qiu H, Wang Q, Zhang J, Song H.

Indian J Pharmacol. 2016 May-Jun;48(3):258-63. doi: 10.4103/0253-7613.182876.

8.

CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese.

Chern HD, Ueng TH, Fu YP, Cheng CW.

Clin Chim Acta. 2006 May;367(1-2):108-13. Epub 2006 Jan 17.

PMID:
16413010
9.

Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC.

Ther Drug Monit. 2010 Jun;32(3):338-45. doi: 10.1097/FTD.0b013e3181d925bb.

PMID:
20386359
10.
11.

[Establishment and preliminary validation of warfarin maintenance dose algorithm in Chinese Han Population].

Lou Y, Hua L, Han L, Li Y, Zhang X, Tang M, Yu H, Liu Z, Wang W, Xu J, Liu H, Li Y.

Zhonghua Xin Xue Guan Bing Za Zhi. 2014 May;42(5):384-8. Chinese.

PMID:
25042915
12.

Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.

Peng Q, Huang S, Chen X, Yuan Y, Yu Y, Tao L, Zhang Z, Xu M.

Pharmacogenomics. 2015;16(13):1465-74. doi: 10.2217/pgs.15.87. Epub 2015 Aug 10.

PMID:
26255607
13.

Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement.

Liu R, Cao J, Zhang Q, Shi XM, Pan XD, Dong R.

Medicine (Baltimore). 2017 Jan;96(2):e5658. doi: 10.1097/MD.0000000000005658.

14.

Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.

Roper N, Storer B, Bona R, Fang M.

J Mol Diagn. 2010 May;12(3):283-91. doi: 10.2353/jmoldx.2010.090110. Epub 2010 Mar 12.

15.

The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.

Yildirim H, Tamer L, Sucu N, Atik U.

Med Princ Pract. 2008;17(6):464-7. doi: 10.1159/000151568. Epub 2008 Oct 3.

16.

A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Lee SJ, Jang YJ, Cha EY, Kim HS, Lee SS, Shin JG.

Br J Clin Pharmacol. 2010 Aug;70(2):213-21. doi: 10.1111/j.1365-2125.2010.03688.x.

17.

Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.

Liu Y, Yang J, Xu Q, Xu B, Gao L, Zhang Y, Zhang Y, Wang H, Lu C, Zhao Y, Yin T.

Thromb Res. 2012 Sep;130(3):435-40. doi: 10.1016/j.thromres.2012.02.003. Epub 2012 Feb 27.

PMID:
22374335
18.

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.

Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC.

Clin Pharmacol Ther. 2004 Sep;76(3):210-9.

PMID:
15371982
19.

Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients.

Li X, Liu R, Luo ZY, Yan H, Huang WH, Yin JY, Mao XY, Chen XP, Liu ZQ, Zhou HH, Zhang W.

Pharmacogenomics. 2015;16(6):583-90. doi: 10.2217/pgs.15.26. Epub 2015 Apr 15.

PMID:
25872772
20.

Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement.

Zhu YB, Hong XH, Wei M, Hu J, Chen X, Wang SK, Zhu JR, Yu F, Sun JG.

Acta Pharmacol Sin. 2017 Mar;38(3):434-442. doi: 10.1038/aps.2016.163. Epub 2017 Feb 20.

PMID:
28216623

Supplemental Content

Support Center